Company intelligence / Profile preview

Oblenio Bio

Oakland, California, United States

Ownership: Private
Development stage: Other

Overview

Oblenio Bio is engaged in developing LBL-051, a first-in-class tri-specific T-cell engager antibody targeting CD19, BCMA, and CD3 for the treatment of autoimmune diseases. The company is newly formed and preparing to enter clinical studies. Its approach, based on dual B cell targeting, aims to deliver a more complete and durable immune reset compared to therapies targeting CD19 or BCMA alone. Clinical results for the specific asset (LBL-051) have not yet been reported as it is being advanced toward first-in-human studies.

Therapeutic areas: Immunology
Modalities: AntibodyT cell engagerTri-specific antibody
Industry: Biotech

Drug pipeline

2 assets

LBL-051

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Aditum BioLeads Biolabs

Beyond the preview

Go deeper on Oblenio Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oblenio Bio.

Explore the full profile